Otc - Active Ingredient
Chlorpheniramine Maleate 4mg
The following Structured Product Label (SPL) was submitted to the FDA by Strive Pharmaceuticals Inc for the product Chlorpheniramine Maleate 4mg (NDC 70692-113). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding otc - active ingredient, inactive ingredient, dosage & administration, indications & usage, warnings, otc - keep out of reach of children, otc - purpose, other safety information, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Chlorpheniramine Maleate 4mg
D&C yellow #10, lactose anhydrous, magnesium stearate, microcrystalline cellulose, pregelatinized starch
| adults and children 12 yers of age and over | 1 tablet every 4 to 6 hours, do not take more than 6 tablets in 24 hours |
| children 6 to under 12 years of age | 1/2 tablet (break tablet in half) every 4 to 6 hours, not to exceed 3 whole tablets in 24 hours |
| children under 6 years of age | ask a doctor |
temporarily relieves the following symptoms due to hay fever or other upper respiratory allergies
Ask a doctor before use if you have
Ask a doctor or a pharmacist before use if
you sre taking sedatives or tranquilzers
When using this product
If pregnant or breast-feeding,
ask a health professional before use
Keep out of reach of children
Overdose warning: In case of accidental overdose, get medical help or contact a Poison Control Center right away. Prompt medical attention is critical for adults as well as for children even if you do not notice any signs or symptoms.
Keep out of reach of children
Overdose Warning: In case of accidental overdose, get medical help or contact a Poison Control Center right away. Prompt medical attention is critical for adults as well as for children even if you do not notice any signs or symptoms.
Antihistamine
* Please review the disclaimer below.